All CIRM Grants

Institution Researcher name Grant Type Grant Title Award Value
City of Hope, Beckman Research Institute David DiGiusto Early Translational II Development of RNA-based approaches to stem cell gene therapy for HIV $3,097,160
University of California, Los Angeles Sophie Deng Early Translational II Regeneration of Functional Human Corneal Epithelial Progenitor Cells $1,524,947
University of California, Irvine Henry Klassen Early Translational II Human retinal progenitor cells as candidate therapy for retinitis pigmentosa $1,803,768
Scripps Research Institute Peter Schultz Early Translational II Cartilage Regeneration by the Chondrogenic Small Molecule PRO1 during Osteoarthritis $6,047,249
iPierian, Inc. John Dimos Early Translational II New Drug Discovery for SMA using Patient-derived Induced Pluripotent Stem Cells $2,410,000
University of California, Los Angeles Sophie Deng Early Translational II Regeneration of Functional Human Corneal Epithelial Progenitor Cells $697,507
University of California, Davis Roslyn Isseroff Early Translational II Bone Marrow Mesenchymal Stem Cells to Heal Chronic Diabetic Wounds $4,629,747
University of California, San Francisco Markus Muschen Early Translational II Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication $2,756,536
University of California, San Francisco Arturo Alvarez-Buylla Early Translational II Inhibitory Nerve Cell Precursors: Dosing, Safety and Efficacy $1,564,016
University of California, Los Angeles Bruno Peault Early Translational II Harnessing native fat-residing stem cells for bone regeneration $5,359,076
University of California, Irvine Brian Cummings Early Translational II Neural restricted, FAC-sorted, human neural stem cells to treat traumatic brain injury $1,517,767
Cedars-Sinai Medical Center Dan Gazit Early Translational II Systemic Adult Stem Cell Therapy for Osteoporosis-Related Vertebral Compression Fractures $1,927,698
Children's Hospital of Los Angeles Markus Muschen Early Translational II Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication $850,769
City of Hope, Beckman Research Institute Yanhong Shi Early Translational II Developing a therapeutic candidate for Canavan disease using induced pluripotent stem cell $1,835,983
Stanford University Michele Calos Early Translational II Stem Cell Therapy for Duchenne Muscular Dystrophy $2,267,261
Buck Institute for Age Research Xianmin Zeng Early Translational II Banking transplant ready dopaminergic neurons using a scalable process $4,983,013
University of California, Irvine leif Havton Early Translational II Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons $1,527,011
Vitalant Research Institute Elizabeth Read Conference Translation of Stem Cell Therapies: Strategies and Best Practices for PreClinical Developments $25,000
University of California, San Francisco Emmanuelle Passegue Conference CA-HSCI 1st Generation Stem Cell PI Meeting $20,000
International Society for Stem Cell Research Irving Weissman Conference ISSCR 8th Annual Meeting - San Francisco $62,475
Sanford Burnham Prebys Medical Discovery Institute Robert Wechsler-Reya Research Leadership The role of neural stem cells in cerebellar development, regeneration and tumorigenesis $5,226,049
Sanford Burnham Prebys Medical Discovery Institute Huei-sheng Chen Basic Biology II Endothelial cells and ion channel maturation of human stem cell-derived cardiomyocytes $1,587,610
University of California, Davis William Murphy Transplantation Immunology Donor natural killer (NK) cells as “veto” cells to promote donor-specific tolerance $1,257,601
University of California, San Francisco John Rubenstein Basic Biology II MGE Enhancers to Select for Interneuron Precursors Produced from Human ES Cells $1,387,800
Stanford University Robert Negrin Transplantation Immunology Regulatory T cell induced tolerance to ESC transplantation $1,382,658
Stanford University Garry Nolan Basic Biology II Kinase signaling analysis of iPS cell reprogramming and differentiation $1,343,100
La Jolla Institute for Allergy and Immunology Anjana Rao Transplantation Immunology Generation of regulatory T cells by reprogramming $1,464,446
University of California, Irvine Aileen Anderson Basic Biology II Role of the microenvironment in human iPS and NSC fate and tumorigenesis $1,256,194
University of California, Berkeley David Raulet Transplantation Immunology Inactivating NK cell reactivity to facilitate transplantation of stem cell derived tissue $952,896
University of California, Irvine Marian Waterman Basic Biology II TCF-3: A Wnt Pathway Effector and Nanog Regulator in Pluripotent Stem Cell Self-Renewal $1,259,879
University of California, Berkeley Ellen Robey Transplantation Immunology Human Immune System Mouse models as preclinical platforms for stem cell derived grafts $1,005,605
University of California, San Diego Dong-Er Zhang Basic Biology II RUNX1 in maintenance, expansion, and differentiation of therapeutic pluripotent stem cells $1,371,540
Stanford University Judith Shizuru Transplantation Immunology Purified allogeneic hematopoietic stem cells as a platform for tolerance induction $1,233,275
University of California, San Diego Kun-Liang Guan Basic Biology II The function of YAP in human embryonic stem cells $1,245,693
University of California, San Francisco Mark Anderson Transplantation Immunology Stem cell differentiation to thymic epithelium for inducing tolerance to stem cells $1,314,089
University of Southern California Terrence Town Transplantation Immunology Role of HLA in neural stem cell rejection using humanized mice $353,249
University of California, Los Angeles Benhur Lee Basic Biology II The EphrinB2/EphB4 axis in regulating hESC pluripotency and differentiation $1,371,936
University of California, San Francisco Jeffrey Bluestone Transplantation Immunology Stem cell tolerance through the use of engineered antigen-specific regulatory T cells $1,152,768
Stanford University Kenneth Weinberg Transplantation Immunology Engineered immune tolerance by Stem Cell-derived thymic regeneration $1,271,729
Stanford University Aaron Hsueh Basic Biology II Maturation of Human Oocytes for SCNT and Embryonic Stem Cell Derivation $1,309,018
Stanford University Christopher Contag Transplantation Immunology Engineering Embryonic Stem Cell Allografts for Operational Tolerance $1,411,338
University of California, San Diego Yang Xu Transplantation Immunology Induction of immune tolerance to human embryonic stem cell-derived allografts $1,192,680
Salk Institute for Biological Studies Ronald Evans Basic Biology II Molecular Characterization and Functional Exploration of Nuclear Receptors in hiPSCs $1,712,880
University of California, Los Angeles Gay Crooks Transplantation Immunology Engineering Thymic Regeneration to Induce Tolerance $1,235,445
Cedars-Sinai Medical Center Terrence Town Transplantation Immunology Role of HLA in neural stem cell rejection using humanized mice $1,119,385
iPierian, Inc. Irene Griswold-Prenner Basic Biology II Cellular Reprogramming: Dissecting the Molecular Mechanism and Enhancing Efficiency $1,458,000
Scripps Research Institute Nicholas Gascoigne Transplantation Immunology Role of Innate Immunity in hematopoeitic stem cell-mediated allograft tolerance $1,705,554
University of California, Davis Eric Kurzrock Basic Biology II Differentiation of Human Embryonic Stem Cells into Urothelium $849,037
Palo Alto Veterans Institute for Research Husein Hadeiba Transplantation Immunology Application of Tolerogenic Dendritic Cells for Hematopoietic Stem Cell Transplantation $733,061
Palo Alto Veterans Institute for Research Tony Wyss-Coray Basic Biology II Systemic Protein Factors as Modulators of the Aging Neurogenic Niche $1,159,806
Escape Therapeutics, Inc Basil Hantash Transplantation Immunology Development of an immune tolerant hESC source for allogeneic cell therapy applications $1,453,040
University of California, Los Angeles Douglas Black Basic Biology II Programs of alternative splicing regulation by polypyrimidine tract binding protein $1,344,562
Scripps Research Institute Jeanne Loring Transplantation Immunology Thymus based tolerance to stem cell therapies $1,108,921
University of California, Los Angeles Yong Kim Basic Biology II Novel Mechanism in Self-Renewal/Differentiation of Human Embryonic Stem Cells $1,259,371
University of California, San Francisco Tippi MacKenzie Transplantation Immunology Maternal and Fetal Immune Responses to In Utero Hematopoietic Stem Cell Transplantation $1,230,869
Stanford University Steven Artandi Basic Biology II Self-renewal and senescence in iPS cells derived from patients with a stem cell disease $931,285
University of California, San Diego Martin Marsala Transplantation Immunology Induction of immune tolerance after spinal grafting of human ES-derived neural precursors $1,387,800
University of California, Irvine Peter Donovan Conference Systems Biology of Stem Cells $25,000
University of California, San Diego Dennis Carson Disease Team Research I Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) $19,999,826
Stanford University Alfred Lane Disease Team Research I iPS Cell-Based Treatment of Dominant Dystrophic Epidermolysis Bullosa $11,039,208
City of Hope, Beckman Research Institute Karen Aboody Disease Team Research I Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials $17,890,623
Stanford University Gary Steinberg Disease Team Research I Embryonic-Derived Neural Stem Cells for Treatment of Motor Sequelae following Sub-cortical Stroke $17,244,851
University of California, Los Angeles Dennis Slamon Disease Team Research I Therapeutic Opportunities To Target Tumor Initiating Cells in Solid Tumors $19,979,660
University of California, Los Angeles Donald Kohn Disease Team Research I Stem Cell Gene Therapy for Sickle Cell Disease $8,833,695
Stanford University Irving Weissman Disease Team Research I Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells $18,759,276
ViaCyte, Inc. Allan Robins Disease Team Research I Cell Therapy for Diabetes $22,999,933
Cedars-Sinai Medical Center Eduardo Marbán Disease Team Research I Autologous cardiac-derived cells for advanced ischemic cardiomyopathy $5,560,232
City of Hope, Beckman Research Institute John Zaia Disease Team Research I ZINC FINGER NUCLEASE-BASED STEM CELL THERAPY FOR AIDS $14,536,969
University of California, Los Angeles Irvin Chen Disease Team Research I HPSC based therapy for HIV disease using RNAi to CCR5. $9,905,604
University of California, San Francisco Mitchel Berger Disease Team Research I Stem Cell-Mediated Oncocidal Gene Therapy of Glioblastoma (GBM) $6,214,914
Calimmune, Inc. Geoff Symonds Disease Team Research I GENE-MODIFIED HEMATOPOIETIC STEM/PROGENITOR CELL BASED THERAPY FOR HIV DISEASE $8,278,722
University of Southern California Mark Humayun Disease Team Research I Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) $18,904,916
University of California, San Diego Lawrence Goldstein Disease Team Research I Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis $5,694,308
University of California, Los Angeles Irvin Chen Early Translational from Disease Team Conversion Development of a humanized mouse model for testing anti-HIV HSPC gene therapy strategies in HIV-1 infected mice. $1,505,000
University of California, San Diego Lawrence Goldstein Early Translational from Disease Team Conversion Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis $4,139,754
Sanford Consortium for Regenerative Medicine Edward Holmes Conference Stem Cell Meeting on the Mesa $40,000
University of California, San Diego Karl Willert Basic Biology I WNT signaling and the control of cell fate decisions in human pluripotent stem cells. $1,329,298
University of California, Los Angeles Robb Maclellan Basic Biology I Human Cardiovascular Progenitors, their Niches and Control of Self-renewal and Cell Fate $917,667
University of California, Davis Min Zhao Basic Biology I Directing migration of human stem cells with electric fields $816,228
University of Southern California Wange Lu Basic Biology I Defining the molecular mechanisms of somatic cell reprogramming $1,365,580
University of California, Los Angeles Luisa Iruela-Arispe Basic Biology I Molecular Characterization and Functional Exploration of Hemogenic Endothelium $1,371,477
University of California, Los Angeles Bennett Novitch Basic Biology I Molecular Characterization of hESC and hIPSC-Derived Spinal Motor Neurons $1,229,922
University of Southern California Martin Pera Basic Biology I The stem cell microenvironment in the maintenance of pluripotency and reprogramming $1,325,723
University of California, Los Angeles Michael Teitell Basic Biology I Mitochondrial Metabolism in hESC and hiPSC Differentiation, Reprogramming, and Cancer $1,323,029
Stanford University Susan McConnell Basic Biology I Identification and characterization of human ES-derived DA neuronal subtypes $1,404,853
University of California, San Diego Eugene Yeo Basic Biology I RNA Binding Protein-mediated Post-transcriptional Networks Regulating HPSC Pluripotency $1,308,901
Stanford University Julien Sage Basic Biology I The retinoblastoma (RB) gene family in cellular reprogramming $1,357,085
Stanford University Helen Blau Basic Biology I Molecular Mechanisms of Reprogramming towards Pluripotency $1,408,332
City of Hope, Beckman Research Institute Richard Jove Conference Innovation and Translational Stem Cell Therapy for Diabetes and Neurological Diseases: Paving the way for real life solutions $14,878
University of California, San Francisco Arnold Kriegstein Conference UCSF Frontiers of Neural Stem Cells Symposium $35,000
Stanford University Hank Greely Conference Stem Cell Policy: Understanding the Scientific and Legal Challenges Ahead $5,838
ViaCyte, Inc. Olivia Kelly Early Translational I Methods for detection and elimination of residual human embryonic stem cells in a differentiated cell product $5,405,397
Scripps Health Darryl D'Lima Early Translational I Stem Cell-Based Therapy for Cartilage Regeneration and Osteoarthritis $3,118,431
Scripps Research Institute Martin Friedlander Early Translational I Autologous Retinal Pigmented Epithelial Cells Derived from Induced Pluripotent Stem Cells for the Treatment of Atrophic Age Related Macular Degeneration $5,806,321
Gladstone Institutes, J. David Warner Greene Early Translational I Maximizing the Safety of Induced Pluripotent Stem Cells as an Infusion Therapy: Limiting the Mutagenic Threat of Retroelement Retrotransposition during iPSC Generation, Expansion and Differentiation $1,280,001
Jackson Labs Pali Kaur Early Translational I Mouse Models for Stem Cell Therapeutic Development $3,759,134
Parkinson's Institute J. William Langston Early Translational I Using patient-specific iPSC derived dopaminergic neurons to overcome a major bottleneck in Parkinson's disease research and drug discovery $3,698,646
Stanford University Jill Helms Early Translational I Enhancing healing via Wnt-protein mediated activation of endogenous stem cells $6,464,126
University of California, Los Angeles Gabriel Travis Early Translational I Development of a Stem Cell-based Transplantation Strategy for Treating Age-related Macular Degeneration $5,487,136
Salk Institute for Biological Studies Inder Verma Early Translational I Curing Hematological Diseases $5,979,252

Pages

Icon for xls export